BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Protiva Biotherapeutics Announces INEX Pharmaceuticals (IEX.TO) Bankruptcy Petition Withdrawn


4/24/2007 9:53:12 AM

VANCOUVER, BRITISH COLUMBIA--(MARKET WIRE)--Apr 23, 2007 -- Protiva Biotherapeutics Inc. today announced that Inex Pharmaceuticals Corporation has withdrawn, with the leave of the Supreme Court of British Columbia, its bankruptcy petition which sought to have Protiva declared bankrupt.

The bankruptcy petition was filed by Inex on February 26, 2007 on the basis that Protiva had not paid Inex $71,882.89 for certain patent costs incurred by Inex between July 2006 and December 2006. As Inex was informed at the time of its submission, the reason Protiva did not reimburse Inex for its costs was because the patents in question are at issue in the ongoing litigation between the companies, and not because Protiva lacked the available funds to do so.

To ensure the petition was withdrawn expeditiously and to eliminate the legal costs of fighting it, Protiva has reimbursed Inex for the total amount owed.

"We are pleased that this petition, which in our view was frivolous to begin with, has been withdrawn," said Protiva's President and CEO, Dr. Mark Murray. "We fully expect Inex will continue its campaign against Protiva. For our part, we will focus on our business and continue to pursue our claims against Inex in court, where we expect to prevail. In the US, Sirna and Merck underestimated the validity of our claims, and have now found themselves enjoined by the California Superior Court from using our intellectual property. We expect to have the same kind of success against Inex. In both cases, we will be seeking to protect our intellectual property as well as substantial monetary damages."

About Protiva

Founded in 2001, Protiva Biotherapeutics Inc. is focused on the development of nucleic acid based pharmaceutical products to fight serious human diseases, such as cancer, influenza (including H5N1), Ebola, inflammatory diseases and other chronic viral infections. Protiva's proprietary Stable Nucleic-Acid Lipid Particle (SNALP) technology is an encapsulation and delivery system for nucleic acid payloads, such as short interfering RNA (siRNA), to target cells. It represents a breakthrough in the field of RNA interference.

Protiva is headquartered in Vancouver, B.C. with offices in Seattle, Washington. For more information, visit www.protivabio.com.

Contact: Contacts: Protiva Biotherapeutics Inc. Mark J. Murray, PH.D. President and Chief Executive Officer Vancouver: (604) 630-5063 Website: http://www.protivabio.com

Longview Communications Inc. David Ryan Media contact (604) 694-6031 Email: dryan@longviewcomms.ca

Source: Protiva Biotherapeutics Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES